Dr. Thomas Ortel, M.D.
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Medical school
- Indiana University School of Medicine (1985)
- Years since graduation
- 41
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 191
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1985Medical school: Indiana University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
NC license 37916
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Duke University Hospital Durham, NC
- Duke Regional Hospital Durham, NC
Medical groups
- Duke Health Integrated Practice, Inc (3,185 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 191
- Services billed
- 363
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Coagulation function screening test with interpretation and report | 83 | 62 |
| Established patient office or other outpatient visit, 30-39 minutes | 56 | 53 |
| Established patient office or other outpatient visit, 20-29 minutes | 21 | 21 |
| New patient office or other outpatient visit, 45-59 minutes | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Durham, NC | 108 |
| Warfarin Sodium Other prescribers in Durham, NC | 69 |
| Jantoven (warfarin sodium) Other prescribers in Durham, NC | 65 |
| Xarelto (rivaroxaban) Other prescribers in Durham, NC | 43 |
| Enoxaparin Sodium Other prescribers in Durham, NC | 28 |
| Oxycodone Hcl Other prescribers in Durham, NC | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 7 payments worth $28,788 in total to this clinician.
| F. Hoffmann-la Roche AG | $24,108 |
|---|---|
| Alexion Pharmaceuticals, Inc. | $4,680 |
| Consulting Fee | $16,750 |
|---|---|
| Travel and Lodging | $11,840 |
| Food and Beverage | $198 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| F. Hoffmann-la Roche AG May 6, 2025 | Travel and Lodging travel to London, Great Britain (UK) | $11,374 |
| F. Hoffmann-la Roche AG May 6, 2025 | Consulting Fee | $8,790 |
| Alexion Pharmaceuticals, Inc. Nov 19, 2025 | Consulting Fee | $4,680 |
| F. Hoffmann-la Roche AG May 19, 2025 | Consulting Fee | $3,280 |
| F. Hoffmann-la Roche AG May 6, 2025 | Travel and Lodging travel to London, Great Britain (UK) | $373 |
| F. Hoffmann-la Roche AG May 6, 2025 | Travel and Lodging travel to London, Great Britain (UK) | $93.33 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $443,001 in research payments for these studies, mostly to the institutions running them.
- A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)
Takeda Pharmaceuticals U.S.A., Inc. · Completed · NCT03393975 - A phase 3B, prospeca phase 3B, prospective, open-label, multicenter, single treatment arm, continuation study of the safety and efficacy of TAK-755 (RADAMTS-13, also known as bax 930/SHP655) in the prophylactic and on…
Takeda Pharmaceuticals U.S.A., Inc. - Study name not reported
Instrumentation Laboratory Company - A study of TAK-755 (RADAMTS13) with little to no plasma exchange (pex) treatment in adults with immune-mediated thrombotic thrombocytopenic purpura (ittp)
Takeda Pharmaceuticals U.S.A., Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.